Scientific Department, Velleja Research, Milan, Italy -
Digestive Endoscopy Unit and Gastroenterology, Fondazione Poliambulanza, Brescia, Italy -
Minerva Obstet Gynecol. 2021 Oct;73(5):621-631. doi: 10.23736/S2724-606X.21.04752-7. Epub 2021 Apr 20.
Vaginal microbiotas can be clustered into five different possible categories (CST I to V), according to their bacterial dominance. In CST I, the dominance of Lactobacillus crispatus seems to correlate with better vaginal health and with a lower incidence of sine causa infertility, preterm delivery, bacterial vaginosis, and viral (including human papillomavirus; HPV) infection. According to the same method of classifying the vaginal microbiome, CST IV (non-Lactobacillus-dominated) demonstrates a higher incidence of disorders.
In an open, non-controlled study, we enrolled 35 HPV-positive women who mostly (N.=24) demonstrated CST IV status, with the other individuals categorized as having either CST III (N.=10) or CST II (N.=1) microbiotas.
After 90 days of oral treatment with a probiotic (L. crispatus M247) we observed a reduction of approximately 70% in HPV positivity and a significant change in CST status with 94% of women now classified as CST I.
Despite the limitations of our study, it is the first demonstration that it is possible to intervene orally with an L. crispatus probiotic to bring about a change in CST status and, in parallel, increased HPV clearance.
根据细菌优势，阴道微生物群可分为五个不同的可能类别（CST I 至 V）。在 CST I 中，优势乳杆菌似乎与更好的阴道健康相关，与无因不孕、早产、细菌性阴道病和病毒（包括人乳头瘤病毒；HPV）感染的发生率较低相关。根据阴道微生物群的相同分类方法，CST IV（非乳杆菌主导）显示出更高的疾病发生率。
在一项开放、非对照研究中，我们招募了 35 名 HPV 阳性妇女，她们主要（N=24）表现出 CST IV 状态，其他个体分为 CST III（N=10）或 CST II（N=1）微生物群。
经过 90 天的口服益生菌（L. crispatus M247）治疗，我们观察到 HPV 阳性率降低了约 70%，CST 状态发生了显著变化，94%的女性现在被归类为 CST I。
尽管我们的研究存在局限性，但这是首次证明可以通过口服乳杆菌益生菌进行干预，以改变 CST 状态，并同时增加 HPV 清除率。
